José Trevejo

José brings his experience and passion for leading research and development teams in the advancement of novel therapeutics for serious and rare diseases. Before joining Tarsus, José served as Chief Development Officer for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, he was Vice President, Clinical Development at Cyclerion Therapeutics where he helped advance a diverse clinical pipeline in GI, cardiac, and rare disease. José joined Ironwood/Cyclerion from Visterra, where he was a member of the Executive Team and led the pre-clinical and clinical development of novel biologics for infectious and rare diseases. Prior to Visterra, he held clinical development roles at Genentech and Vertex Pharmaceuticals.

José completed his clinical training including a sub-specialization in Infectious Disease at Brigham and Women’s Hospital/Beth-Israel Deaconess Medical Center/Harvard Medical School and earned his MD and PhD from the Tri-Institutional MD-PhD program at Cornell-Rockefeller-Sloan Kettering in New York City.